A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT04632108 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

199

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Solid Tumor

Interventions

DRUG: ASKB589 Injection

Sponsor

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Collaborators

[object Object]